Company Analysis
Sign in

Xenon Pharmaceuticals Inc. (XENE)

Nasdaq: XENE · Pharmaceutical Preparations · filing with the SEC since 2013
Full chart Alerts Compare
Grade4.6
◀ Past 4.3● Present 5.1▶ Future 4.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

110 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Xenon Pharmaceuticals Inc.’s names, not what it holds today.

Patents granted
110
110 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 4 in 2024 and 1 in 2023
Applications published
151
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry12
Pharmaceuticals4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Xenon Pharmaceuticals Inc. its own name
CA, as the owner printed on each patent
110 granted
111 published
Xenon Pharmaceuticals Inc. its own name
named as the applicant on its applications, in CA
0 granted
40 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jun 3, 202512,319,657Solid state crystalline forms of a selective potassium channel modulatorOrganic fine chemistryXenon Pharmaceuticals Inc.
Dec 31, 202412,178,811Methods of treating depressive disordersPharmaceuticalsXenon Pharmaceuticals Inc.
Dec 24, 202412,171,759Methods and uses for treating anhedoniaPharmaceuticalsXenon Pharmaceuticals Inc.
Aug 6, 202412,054,486Pyridine derivatives and their use as sodium channel activatorsOrganic fine chemistryXenon Pharmaceuticals Inc.
Apr 16, 202411,957,675Methods and uses for treating anhedoniaPharmaceuticalsXenon Pharmaceuticals Inc.
May 2, 202311,639,351Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agentsOrganic fine chemistryXenon Pharmaceuticals Inc.
May 10, 202211,325,902Benzenesulfonamide compounds and their use as therapeutic agentsOrganic fine chemistryXenon Pharmaceuticals Inc.
Apr 12, 202211,299,490Benzenesulfonamide compounds and their use as therapeutic agentsOrganic fine chemistryXenon Pharmaceuticals Inc.
Dec 21, 202111,203,572Substituted benzamides and methods of use thereofOrganic fine chemistryXenon Pharmaceuticals Inc.
Nov 16, 202111,174,268Benzenesulfonamide compouds and their use as therapeutic agentsOrganic fine chemistryXenon Pharmaceuticals Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 4, 20252025/0275957METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENERPharmaceuticalsXenon Pharmaceuticals Inc.
Jul 10, 20252025/0221980METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENERPharmaceuticalsXenon Pharmaceuticals Inc.
Jul 3, 20252025/0214970PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORSOrganic fine chemistryXenon Pharmaceuticals Inc.
Jun 12, 20252025/0186426METHODS AND USES FOR TREATING ANHEDONIAPharmaceuticalsXenon Pharmaceuticals Inc.
Apr 24, 20252025/0129044PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORSOrganic fine chemistryXenon Pharmaceuticals Inc.
Apr 3, 20252025/0108044METHODS OF TREATING DEPRESSIVE DISORDERSPharmaceuticalsXenon Pharmaceuticals Inc.
Feb 20, 20252025/0059189PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORSOrganic fine chemistryXenon Pharmaceuticals Inc.
Dec 12, 20242024/0408076METHODS AND USES FOR TREATING ANHEDONIAPharmaceuticalsXenon Pharmaceuticals Inc. · patent 12,171,759 granted from it
Dec 12, 20242024/0408075CONJOINT THERAPY FOR TREATING SEIZURE DISORDERSPharmaceuticalsXenon Pharmaceuticals Inc.
Oct 17, 20242024/0342156METHODS FOR TREATING PAINPharmaceuticalsXenon Pharmaceuticals Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Organic fine chemistry 5.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton XENE · research, not advice